News articles about Lannett (NYSE:LCI) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lannett earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1083037691679 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Lannett Company, Inc. (LCI) Expected to Announce Quarterly Sales of $192.54 Million (americanbankingnews.com)
- Lannett Co., Inc. :LCI-US: Earnings Analysis: Q1, 2018 By the Numbers : December 25, 2017 (finance.yahoo.com)
- Lannett Co., Inc. breached its 50 day moving average in a Bearish Manner : LCI-US : December 22, 2017 (finance.yahoo.com)
- Lannett Company, Inc. (LCI) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- 36 Stocks Moving In Thursday’s Mid-Day Session – Benzinga (benzinga.com)
Shares of Lannett (LCI) opened at $24.15 on Thursday. The company has a current ratio of 2.52, a quick ratio of 1.90 and a debt-to-equity ratio of 1.44. Lannett has a 12-month low of $14.90 and a 12-month high of $30.35. The company has a market capitalization of $906.68, a price-to-earnings ratio of 21.56, a P/E/G ratio of 1.58 and a beta of 2.85.
Several research firms recently commented on LCI. ValuEngine raised Lannett from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Zacks Investment Research cut Lannett from a “buy” rating to a “hold” rating in a research report on Wednesday, December 13th. Oppenheimer reaffirmed a “hold” rating on shares of Lannett in a research report on Monday, December 11th. Finally, BMO Capital Markets increased their price objective on Lannett from $20.00 to $22.00 and gave the company a “market perform” rating in a research report on Monday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $23.60.
In other Lannett news, major shareholder David Farber sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $25.03, for a total value of $250,300.00. Following the transaction, the insider now directly owns 4,211,069 shares of the company’s stock, valued at $105,403,057.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arthur P. Bedrosian sold 7,422 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $25.20, for a total value of $187,034.40. Following the completion of the transaction, the chief executive officer now directly owns 679,001 shares in the company, valued at $17,110,825.20. The disclosure for this sale can be found here. Insiders sold 130,000 shares of company stock worth $3,430,991 over the last three months. Insiders own 14.72% of the company’s stock.
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.